Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02314286|
Recruitment Status : Unknown
Verified December 2014 by Ofer Beharier, Soroka University Medical Center.
Recruitment status was: Not yet recruiting
First Posted : December 11, 2014
Last Update Posted : December 11, 2014
|First Submitted Date ICMJE||November 16, 2014|
|First Posted Date ICMJE||December 11, 2014|
|Last Update Posted Date||December 11, 2014|
|Study Start Date ICMJE||December 2014|
|Estimated Primary Completion Date||July 2016 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||To evaluate the effect of Rosuvastatin on the severe preeclampsia resolution at 48 hours after delivery [ Time Frame: 48 hours ]|
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||No Changes Posted|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery|
|Official Title ICMJE||Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery|
|Brief Summary||Prospective randomized single blind trial. Study population are women diagnosed with severe pre-eclampsia during singleton pregnancy, between 24+0 weeks and 41+6 weeks gestational age. The purpose of the study is to evaluate the effect of Rosuvastatin on the severe preeclampsia resolution at 48 hours after delivery. After screening and signing an informed consent form, before entering delivery room, a randomization 1:1 will be carried. 50 women will be in the treatment arm while 50 will be in the control arm. Both groups will be treated according to ACOG (The American College of Obstetricians and Gynecologists has the following clinical guidelines related to deliveries before 39 weeks) guidelines. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.|
Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks' postpartum. It is clinically defined by as blood pressure ≥140 mmHg systolic and ≥90 mmHg diastolic diagnosed for the first time after 20 weeks' gestation together with >300mg proteinuria/24 hours.
The global incidence of preeclampsia has been estimated at 5-14% of all pregnancies. Pre-eclampsia affects approximately 6-8% of all pregnancies worldwide. Pre-eclampsia affects 3-5% of all first time pregnancies, but early severe pre-eclampsia occurs in only 1:200 pregnancies.
Significant risk factors for pre-eclampsia are as follows: Nulliparity, age >40 years, black race, family history, chronic renal disease, chronic hypertension, antiphospholipid syndrome, diabetes mellitus , multiple gestation and high body mass index.
Mild preeclampsia is defined as the presence of hypertension (BP ≥140/90 mm Hg) on 2 occasions, at least 6 hours apart, but without evidence of end-organ damage.
Severe preeclampsia is defined as the presence of 1 of the following symptoms or signs in the presence of preeclampsia:
marked elevation of blood pressure (>160/110 mmHg), severe proteinuria (>5 g/24 hours), or evidence of central nervous system (CNS) dysfunction (headaches, blurred vision, seizures, coma), renal dysfunction (oliguria or creatinine > 1.5 mg/dL), pulmonary edema, hepatocellular injury (ALT > 2-fold the upper limits of normal), hematologic dysfunction (platelet count < 100,000/L or DIC), or placental dysfunction (oligohydramnios or severe intrauterine growth restriction). The HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome is a special subgroup of severe preeclampsia and is a major cause of morbidity and mortality.
Eclampsia is defined as seizures that cannot be attributable to other causes in a woman with preeclampsia.
The optimal management of a woman with preeclampsia depends on gestational age and disease severity Management of preeclampsia is challenging because it requires the clinician to balance the health of the mother and fetus simultaneously. Patients with mild preeclampsia are often induced after 37 weeks gestation. Before this, the immature fetus is treated with expectant management with bed rest, close monitoring of blood pressure and renal function, and careful fetal surveillance. For women with severe preeclampsia, induction of delivery should be considered after 34 weeks gestation unless the patient is eligible for expectant management in a tertiary hospital setting. The definitive treatment of preeclampsia is delivery of the fetus and placenta. Anti-hypertensive drugs are essential for severe hypertension (≥160 mmHg systolic or ≥110 mmHg diastolic) for reducing the risk of cerebrovascular accidents. Intravenous Labetalol, Nifedipine or hydralazine are the drugs most commonly used to manage preeclampsia but there is insignificant evidence to indicate which drug is preferable..
Magnesium sulfate is the treatment of choice for the prevention and treatment of eclamptic seizures Where immediate child-birth is not essential, a delay of 24 hours will allow steroids to be given to mature the baby's lungs, although a shorter duration may still be of benefit.
Preeclampsia is associated with short-term and long-term maternal and fetal complications. For the mother, it may lead to eclamptic seizures, stroke, intracranial bleed, uncontrolled hypertension, renal failure, and hemolysis. For the fetus, it may lead to intrauterine growth restriction, placental abruption, and the short-term and long-term complications of prematurity, as well as predisposition to adult cardiovascular and metabolic disorders. Currently, there is no effective therapy to preeclampsia, and delivery remains the only approach to preventing maternal morbidity and mortality. However, this is usually achieved at the expense of premature delivery and its associated morbidities. Moreover, following the delivery, preeclampsia resolved slowly within days, exposing the mother to late complications and increasing treatment cost significantly.
To date, the exact etiology of preeclampsia remains unknown. However, evidence obtained in recent years, supports the theory that angiogenic imbalance is the end common pathway that leads to clinical preeclampsia. During normal pregnancy, vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) promote pro-angiogenic state that regulates vascular tone and glomerular capillary health. In preeclampsia, these proteins are antagonized by excessive placental production of soluble fms-like tyrosine kinase-1 (sFlt-1), thereby creating angiogenic imbalance. After delivery, this imbalance resolves within hours to days correlating with the resolution of the disease. One of the observations that marked sFlt-1 as key player in the pathogenesis of preeclampsia was made in an animal model. It was demonstrated that preeclampsia can be induced in animal model by over expressing sFlt-1 alone. In their model hydrophilic statins treatment decreased sFlt-1 levels and up-regulated VEGF and PlGF levels. Most importantly, statins ameliorated preeclampsia symptoms by improving hypertension and proteinuria in the preeclamptic mice.
Statins are potent inhibitors of cholesterol biosynthesis and used successfully in the primary and secondary prevention of coronary heart disease. Additionally, statins are known to mediate pleiotropic effects via improving endothelial function and attenuating inflammatory responses. Rosuvastatin is a hydrophilic statin, characterized by low permeability through membranes, as the placenta and blood-brain-barrier. In addition, Short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects.
Currently, the food and drug administration classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Evidence for teratogenicity of the hydrophilic statins was never reported probably due to their limited permeability across membranes. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Phase 1
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
|Condition ICMJE||Severe Pre-eclampsia|
|Study Arms ICMJE||
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Unknown status|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||July 2016|
|Estimated Primary Completion Date||July 2016 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages ICMJE||18 Years and older (Adult, Older Adult)|
|Accepts Healthy Volunteers ICMJE||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Not Provided|
|Removed Location Countries|
|NCT Number ICMJE||NCT02314286|
|Other Study ID Numbers ICMJE||sor005514ctil
SCRC14001 ( Other Identifier: soroka )
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement ICMJE||Not Provided|
|Responsible Party||Ofer Beharier, Soroka University Medical Center|
|Study Sponsor ICMJE||Soroka University Medical Center|
|Collaborators ICMJE||Not Provided|
|Investigators ICMJE||Not Provided|
|PRS Account||Soroka University Medical Center|
|Verification Date||December 2014|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP